3SBio Crecimiento futuro

Future controles de criterios 2/6

3SBio se prevé un crecimiento anual de los beneficios y los ingresos de 7.5% y 7.1% respectivamente. Se prevé que el BPA sea de grow en 6.5% al año. Se prevé que la rentabilidad de los fondos propios sea de 13.3% en 3 años.

Información clave

12.6%

Tasa de crecimiento de los beneficios

12.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	34.6%
Tasa de crecimiento de los ingresos	7.6%
Rentabilidad financiera futura	12.3%
Cobertura de analistas	Good
Última actualización	16 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

SHSC:1530 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	10,285	2,300	2,069	N/A	7
12/31/2025	9,445	2,133	1,901	N/A	9
12/31/2024	8,649	1,934	1,376	N/A	9
12/31/2023	7,816	1,549	N/A	N/A	N/A
9/30/2023	7,681	1,733	N/A	N/A	N/A
6/30/2023	7,549	1,929	1,311	2,337	N/A
3/31/2023	7,204	1,922	1,259	2,259	N/A
12/31/2022	6,859	1,915	1,207	2,180	N/A
9/30/2022	6,616	1,823	1,008	1,964	N/A
6/30/2022	6,369	1,719	856	1,794	N/A
3/31/2022	6,376	1,685	663	1,686	N/A
12/31/2021	6,382	1,651	469	1,578	N/A
9/30/2021	6,191	1,342	394	1,513	N/A
6/30/2021	6,000	1,032	318	1,448	N/A
3/31/2021	5,794	934	340	1,396	N/A
12/31/2020	5,588	836	363	1,345	N/A
9/30/2020	5,479	1,095	813	1,620	N/A
6/30/2020	5,370	1,355	1,263	1,896	N/A
3/31/2020	5,344	1,164	1,332	1,892	N/A
12/31/2019	5,318	974	1,401	1,887	N/A
9/30/2019	5,185	1,029	1,257	1,645	N/A
6/30/2019	5,053	1,084	1,113	1,403	N/A
3/31/2019	4,818	1,181	915	1,277	N/A
12/31/2018	4,584	1,277	717	1,150	N/A
9/30/2018	4,393	1,167	695	1,160	N/A
6/30/2018	4,202	1,057	673	1,171	N/A
3/31/2018	3,968	996	752	1,122	N/A
12/31/2017	3,734	935	831	1,074	N/A
9/30/2017	3,467	877	N/A	1,017	N/A
6/30/2017	3,199	818	N/A	960	N/A
3/31/2017	2,998	766	N/A	982	N/A
12/31/2016	2,797	713	N/A	1,004	N/A
9/30/2016	2,492	642	N/A	794	N/A
6/30/2016	2,188	571	N/A	583	N/A
3/31/2016	1,930	548	N/A	519	N/A
12/31/2015	1,673	526	N/A	455	N/A
9/30/2015	1,503	456	N/A	521	N/A
6/30/2015	1,364	341	N/A	534	N/A
3/31/2015	1,247	316	N/A	460	N/A
12/31/2014	1,131	292	N/A	387	N/A
9/30/2014	1,044	238	N/A	301	N/A
12/31/2013	875	96	N/A	217	N/A
9/30/2013	842	95	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: 1530(7.5% al año) es superior a la tasa de ahorro (2%).

Beneficios vs. Mercado: 1530Se prevé que los beneficios de la empresa (12.6% al año) crezcan más deprisa que el mercado Hong Kong (11.7% al año).

Beneficios de alto crecimiento: 1530Se prevé que los beneficios de la empresa crezcan, pero no significativamente.

Ingresos vs. Mercado: 1530(7.6% al año) se prevé que crezca más despacio que el mercado de Hong Kong (8% al año).

Ingresos de alto crecimiento: 1530Se prevé que los ingresos de la empresa (7.1% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: 1530Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (13.3%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

3SBio Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

Recent updates

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Mandi Foam of 3SBio Inc. Approves for Market Launch

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.40 in 1H 2022)

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

Full year 2022 earnings released: EPS: CN¥0.78 (vs CN¥0.65 in FY 2021)

Now 22% undervalued

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Investor sentiment improved over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.65 (vs CN¥0.33 in FY 2020)

3SBio Inc., Annual General Meeting, Jun 22, 2022

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.38 in FY 2019)

3SBio Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

3Sbio Inc. Announces Completion the Enrolment of Subjects for Phase Ii Clinical Study

New 90-day high: HK$8.42

3SBio Inc. Provides Update on License Agreement with AstraZeneca and Hongkong Sansheng

New 90-day high: HK$7.81

New 90-day low: HK$7.06

3Sbio Inc. Receives Milestone Payment of USD 4 Million Upon Commencement of Phase III Clinical Program of SEL-212

New 90-day low: HK$7.19

New 90-day low: HK$8.13

First half earnings released

New 90-day low: HK$8.22

3SBio Inc. to Report First Half, 2020 Results on Aug 17, 2020

New 90-day low - HK$8.98

First half earnings released

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento